Baron Funds released its “Baron Health Care Fund” third-quarter 2025 investor letter, showing a 5.39% rise for Institutional Shares. Insmed Incorporated (NASDAQ:INSM) saw a 11.47% one-month return and shares gained 110.54% over the last 52 weeks, closing at $161.38 per share on October 31, 2025, with a market cap of $34.112 billion.

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company developing therapies for serious pulmonary diseases, with potential to generate over $8 billion in peak sales. Their stock rose after U.S. approval of Brinsupri for non-cystic fibrosis bronchiectasis, a condition affecting an estimated 500,000 patients. Treprostinil palmitil inhalation powder (TPIP) is also showing promise for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Insmed Incorporated (NASDAQ:INSM) was not among the 30 most popular stocks among hedge funds in 2024 Q3. 82 hedge fund portfolios held INSM at the end of the second quarter, a decrease from the previous quarter. While Insmed shows investment potential, some AI stocks may offer greater upside potential and less downside risk. Check out our free report on the best short-term AI stock.

Read more at Yahoo Finance: Approval of Brinsupri Lifted Insmed Incorporated (INSM) in Q3